research use only

Gefitinib-based PROTAC 3 EGFR inhibitor

Cat.No.S0070

Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively.
Gefitinib-based PROTAC 3   EGFR inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 934.51

Jump to

Quality Control

Batch: Purity: 99.99%
99.99

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (107.0 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 934.51 Formula
C47H57ClFN7O8S
Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2230821-27-7 -- Storage of Stock Solutions

Synonyms N/A Smiles CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)C3CC(CN3C(=O)C(C(C)(C)C)NC(=O)CCOCCOCCCCCOC4=C(C=C5C(=C4)C(=NC=N5)NC6=CC(=C(C=C6)F)Cl)OC)O

Mechanism of Action

Targets/IC50/Ki
EGFR
(in HCC827(Exon 19 del) cells)
11.7 nM(DC50)
EGFR
(in H3255 (L858R) cells)
22.3 nM(DC50)
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01164735 Not yet recruiting
Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation
January 2100 --
NCT05763030 Not yet recruiting
Child Sleep
New York State Psychiatric Institute|International Centre for Diarrhoeal Disease Research Bangladesh|Fogarty International Center of the National Institute of Health
April 2027 Not Applicable
NCT02438202 Not yet recruiting
Alzheimer''s Disease
Central Institute of Mental Health Mannheim
December 2026 Not Applicable
NCT06392542 Not yet recruiting
Alcohol Use Unspecified|Relationship Social|Depression Anxiety|Transgenderism
Boston University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)
April 2026 Not Applicable
NCT06077526 Not yet recruiting
Chronic Pain
Bridgewater College
January 13 2026 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map